Goldman Sachs Analysts Predict Massive Surge for Eli Lilly as Growth Trajectory Accelerates
The pharmaceutical landscape is witnessing a significant shift as Eli Lilly and Company continues to solidify its position as a dominant force
by 
Josh Weiner
Josh Weiner